About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
IP: Miguel Segura Ginard Collaborators: Soledad Gallego Melcón Funding agency: Instituto de Salud Carlos III Funding: 208120 Reference: PI20/00530 Duration: 01/01/2021 - 31/12/2023
IP: M Mar Mañu Pereira Collaborators: Pablo Velasco Puyó, Bárbara Tazón Vega, David Beneitez Pastor, Maria Cristina Díaz de Heredia Rubio, Adoración Blanco Alvarez, Thaïs Murciano Carrillo, Amira Idrizovic Funding agency: Instituto de Salud Carlos III Funding: 99220 Reference: PI20/01454 Duration: 01/01/2021 - 30/06/2025
IP: M Mar Mañu Pereira Collaborators: Claire Diot, Raquel Mosull del Campo Funding agency: EUROPEAN COMMISSION Funding: 105250 Reference: ERICA_H2020-SC1-BHC-2020 Duration: 01/03/2021 - 31/08/2025
IP: M Mar Mañu Pereira Collaborators: Reidel , Sara Isabel, Amira Idrizovic , Sara Isabel Reidel Funding agency: EUROPEAN COMMISSION Funding: 434000 Reference: GENOMED4ALL_H2020-SC1-FA-DTS-2018-20 Duration: 01/01/2021 - 30/06/2025
The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.
The European initiative Hope4Kids will strengthen and harmonise paediatric palliative care across Europe, with the aim of ensuring comprehensive, high-quality care for all children living with life-threatening or life-limiting conditions.
The initiative will enable young people aged 12 to 18 to collaborate with campus researchers in the design, development and communication of scientific projects, placing patients and families at the centre of the research process.
